Nota de idioma: o chrome desta página está em português; o corpo longo abaixo permanece em inglês para preservar a precisão das fontes.
Thymosin β4
Also indexed as Tβ4 · Thymosin beta 4
Thymosin β4 is a naturally occurring peptide studied in cell migration, cytoskeletal regulation and tissue repair models. It has a real scientific history, while the online label “TB-500” adds an identity problem.
Last reviewed 2026-09-07 · education only
O que aparece na literatura
Research describes binding to actin and downstream effects on cell movement and repair signaling. Those mechanisms are useful for reading papers, not a clinical recommendation.
History & development
- 1960s
The thymosin field began with work in Abraham White's laboratory at Albert Einstein College of Medicine; the term thymosins was introduced in a 1966 PNAS paper.
- 1970s
Work at the University of Texas Medical Branch advanced purification and characterization of thymic peptides, including the broader thymosin program.
Source: Goldstein historical lecture ↗
- 2015
A review summarized basic and clinical applications of thymosin β4 and the limits of translating regenerative biology into products.
Source: PubMed review ↗
Approved brands & pathway
Thymosin β4 is presented for research-name and evidence literacy. A research name does not authenticate a product or establish a human-use pathway.
Entradas de evidência
Tema: Tissue repair · wound research · Categoria: Tissue repair
Thymosin β4
O que a fonte sustenta
Preclinical and early clinical research interest
Research includes dermal repair models and early clinical studies; endpoints and formulations vary across the literature.
Limite: This is not a recommendation or proof for an unapproved product, route or indication.
Fonte: Review of models and early studies · PubMed Ler fonte ↗
Tema: Tissue repair · naming literacy · Categoria: Tissue repair
TB-500 vs thymosin β4
O que a fonte sustenta
Identity and evidence distinction
Thymosin β4 has a research literature, while “TB-500” is a marketplace name that should not be treated as automatically identical to the studied molecule or formulation.
Limite: A name match does not prove sequence, identity, formulation, bioequivalence, safety or approval.
Fonte: Thymosin β4 review · PubMed Ler fonte ↗
Grade mix in this atlas
Grades describe the cited record for a narrow question. They do not score a marketplace material or make a health decision.
Naming curiosities & useful distinctions
- The beta symbol in Thymosin β4 is part of a peptide name; it does not mean a product grade.
- TB-500 is a marketplace/research name that should not be assumed identical to studied full-length thymosin β4 or any particular formulation.
TB-500 is an identity question
The review literature concerns thymosin β4, while marketplace language may use TB-500. A matching label is not proof of sequence, purity, formulation or equivalence.
The thymosin field predates peptide hype
The historical record starts in the 1960s, long before modern recovery-marketing language. The age of a research field is not proof of a current product.
Nomes no registro
Thymosin history
Allan L. Goldstein and colleagues
Goldstein's historical account describes the early thymosin work and later characterization of thymic peptides.
Early thymosin research
Abraham White
The historical record credits White's laboratory with the studies that led to the isolation and naming of thymosins.